Down-regulation of topoisomerase IIα in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3

Cancer Research

Volumn 57, Issue 22, 1997, Pages 5004-5008

  Mo, Yin Yuan ^a   Wang, Qingjian ^a   Beck, William T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); MERBARONE; TRANSCRIPTION FACTOR SP1;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HALF-LIFE; HUMANS; RNA, MESSENGER; SP3 TRANSCRIPTION FACTOR; THIOBARBITURATES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0030710143     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Watt, P. M., and Hickson, I. D. Structure and function of type II DNA topoisomerases. Biochem J., 303: 681-695, 1994.
2. Nelson, W. G., Liu, L. F., and Coffey, D. S. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (Lond.), 322: 187-189, 1986.
3. Kretzschmar, M., Meisterernst, M., and Roeder, R. G. Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc. Natl. Acad. Sci. USA, 90: 11508-11512, 1993.
4. Isaacs, R. J., Davies, S. L., Wells, N. J., and Harris, A. L. Topoisomerases IIα and β as therapy targets in breast cancer. Anti-Cancer Drugs, 6: 195-211, 1995.
5. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
6. Jenkins, J. R, Ayton, P., and Hickson, I. D. Isolation of cDNA clones encoding the β isozyme of human topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res., 20: 5587-5592, 1992.
7. Tsai-Pflugfelder, M., Liu, L. F., Liu, A. A., Tewey, K. M., Whang-Peng, J., Knutsen, T., Huebner, K., Croce, C. M., and Wang, J. C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc. Natl. Acad. Sci. USA, 85: 7177-7181, 1988.
8. Osheroff, N., Corbett, A. H., and Robinson, M. J. Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv. Pharmacol., 29B: 105-126, 1994.
9. Nitiss, J. L., and Beck, W. T. Antitopoisomerase drug action and resistance. Eur. J. Cancer, 32A: 958-966, 1996.
10. Beck, W. T., Danks, M. K., Wolverton, J. S., Chen, M., Granzen, B., Kim, R., and Suttle, D. P. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv. Pharmacol., 29B: 145-169, 1994.
11. Chen, M., and Beck, W. T. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol. Res., 7: 103-111, 1995.
12. Takano, M., Kohno, K., One, M., Uchida, Y., and Kuwano, M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res., 51: 3951-3957, 1991.
13. Kusumoto, H., Rodgers, Q. E., Boege, F., Raimondi, S. C., and Beck, W. T. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res., 56: 2573-2583, 1996.
14. Andoh, T., Nishizawa, M., Hida, T., Ariyoshi, Y., Takahashi, T., and Ueda, R. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Oncol. Res., 8: 229-238, 1996.
15. Ritke, M. K., and Yalowich, J. C. Altered gene expression in human myeloid leukemia K562 cells selected for resistance to etoposide. Biochem. Pharmacol., 46: 2007-2020, 1993.
16. Potmesil, M., Hsiang, Y. H., Liu, L. F., Bank, B., Grossberg, H., Kirschenbaum, S., Forlenza, T. J., Penziner, A., Kanganis, D., Knowles, D., Tragnos, F., and Silber, R. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res., 48: 3537-3543, 1988.
17. Kawanami, K., Nakamura, T., Ono, M., Kusano, T., Okada, K., Kikuchi, A., Adachi, N., Kohno, K., Higashi, K., and Kuwano, M. Decreased DNA topoisomerase IIα expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. Oncol. Res., 8: 197-206, 1996.
18. Hashimoto, S., Chatterjee, S., Ranjit, G. B., Bao, C., Ford, J., Ganapathi, R., Berger, S. J., and Berger, N. A. Drastic reduction of topoisomerase IIα associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth. Oncol. Res., 7: 407-416, 1996.
19. Hochhauser, D., Stanway, C. A., Harris, A. L., and Hickson, I. D. Cloning and characterization of the 5′-flanking region of the human topoisomerase IIα gene. J. Biol. Chem., 267: 18961-18965, 1992.
20. Wang, Q., Zambetti, G. P., and Suttle, D. P. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol. Cell. Biol., 17: 389-397, 1997.
21. Brandt, T. L., Fraser, D. J., Leal, S., Halandras, P. M., Kroll, A. R., and Kroll, D. J. c-Myb trans-activates the human DNA topoisomerase IIα gene promoter. J. Biol. Chem., 272: 6278-6284, 1997.
22. Kubo, T., Kohno, K., Ohga, T., Taniguchi, K., Kawanami, K., Wada, M., and Kuwano, M. DNA topoisomerase IIα gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res., 55: 3860-3864, 1995.
23. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, pp. 9.1-9.62. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory, 1989.
24. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. Current Protocols in Molecular Biology, pp. 15.0.1-15.8.8. New York: Wiley-Interscience, 1989.
25. Kingsley, C., and Winoto, A. Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol. Cell. Biol., 12: 4251-4261, 1992.
26. Pastan, I., and Gottesman, M. Multiple-drug resistance in human cancer. New Engl. J. Med., 316: 1388-1393, 1987.
27. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., MacKie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
28. Danks, M. K., Yalowich, J. C., and Beck, W. T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res., 47: 1297-1301, 1987.
29. Izquierdo, M. A., van der Zee, A. G. J., Vermorken, J. B., van der Valk, P. Belien, J. A. M., Giaccone, G., Scheffer, G. L., Flens, M. J., Pinedo, H. M., Kenemans, P., Meiger, C. J. L. M., de Vries, E. G. E., and Scheper, R. J. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst., 87: 1230-1237, 1995.
30. Beck, W. T. DNA topoisomerases and tumor cell resistance to their inhibitors. In: R. L. Schilsky, G. A. Milano, and M. J. Ratain (eds.), Principles of Antineoplastic Drug Development and Pharmacology, pp. 487-501. New York: Marcel Dekker, Inc., 1996.
31. Faisst, S., and Meyer, S. Compilation of vertebrate-encoded transcription factors. Nucleic Acids Res., 20: 3-26, 1992.
32. Kadonaga, J. T., Carner, K. R., Masiarz, F. R., and Tjian, R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell, 51: 1079-1090, 1987.
33. Hagen, G., Muller, S., Beato, M., and Suske, G. Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes. Nucleic Acids Res., 20: 5519-5525, 1992.
34. Hagen, G., Muller, S., Beato, M., and Suske, G. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J., 13: 3843-3851, 1994.
35. Udvadia, A. J., Templeton, D. J., and Horowitz, J. M. Functional interactions between the retinoblastoma (Rb) protein and Sp-family members: superactivation by Rb requires amino acids necessary for growth suppression. Proc. Natl. Acad. Sci. USA, 92: 3953-3957, 1995.
36. Sjottem, E., Anderssen, S., and Johansen, T. The promoter activity of long terminal repeats of the HERV-H family of human retrovirus-like elements is critically dependent on Sp1 family proteins interacting with a GC/GT box located immediately 3′ to the TATA box. J. Virol., 70: 188-198, 1996.
37. Dennig, J., Beato, M., and Suske, G. An inhibitor domain in Sp3 regulates its glutamine-rich activation domains. EMBO J., 15: 5659-5667, 1996.
38. Netzker, R., Weigert, C., and Brand, K. Role of the stimulatory proteins Sp1 and Sp3 in the regulation of transcription of the rat pyruvate kinase M gene. Eur. J. Biochem., 245: 174-181, 1997.